Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 6
2011 37
2012 7
2013 4
2014 4
2015 1
2016 1
2017 1
2018 1
2019 2
2020 1
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial.
Peterli R, Wölnerhanssen BK, Peters T, Vetter D, Kröll D, Borbély Y, Schultes B, Beglinger C, Drewe J, Schiesser M, Nett P, Bueter M. Peterli R, et al. Among authors: drewe j. JAMA. 2018 Jan 16;319(3):255-265. doi: 10.1001/jama.2017.20897. JAMA. 2018. PMID: 29340679 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: The Swiss Multicenter Bypass or Sleeve Study (SM-BOSS), a 2-group randomized trial, was conducted from January 2007 until November 2011 (last follow-up in March 2017). Of 3971 morbidly obese patients evaluated for bariatric surgery at 4 S …
DESIGN, SETTING, AND PARTICIPANTS: The Swiss Multicenter Bypass or Sleeve Study (SM-BOSS), a 2-group randomized trial, was conducted from Ja …
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Müller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Leuppi JD, et al. Among authors: bodmer m. JAMA. 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023. JAMA. 2013. PMID: 23695200 Clinical Trial.
DESIGN, SETTING, AND PATIENTS REDUCE: (Reduction in the Use of Corticosteroids in Exacerbated COPD), a randomized, noninferiority multicenter trial in 5 Swiss teaching hospitals, enrolling 314 patients presenting to the emergency department with acute COPD exacerbation, past or p …
DESIGN, SETTING, AND PATIENTS REDUCE: (Reduction in the Use of Corticosteroids in Exacerbated COPD), a randomized, noninferiority multicente …
Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Taegtmeyer AB, Leuppi JD, Kullak-Ublick GA. Taegtmeyer AB, et al. Swiss Med Wkly. 2012 Jul 25;142:w13628. doi: 10.4414/smw.2012.13628. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22833385 Free article. Review.
Roflumilast is a selective phosphodiesterase 4 inhibitor which has been licensed in the European Union since 2010 and in Switzerland since November 2011 as an add-on treatment for patients with chronic obstructive pulmonary disease (COPD) in GOLD (Global Initiative for Chr …
Roflumilast is a selective phosphodiesterase 4 inhibitor which has been licensed in the European Union since 2010 and in Switzerland since N …
Combinatorial QSAR modeling of human intestinal absorption.
Suenderhauf C, Hammann F, Maunz A, Helma C, Huwyler J. Suenderhauf C, et al. Among authors: hammann f. Mol Pharm. 2011 Feb 7;8(1):213-24. doi: 10.1021/mp100279d. Epub 2010 Dec 29. Mol Pharm. 2011. PMID: 21142073
50 results